Inspiremd announces presentation of positive one-year follow-up results from the c-guardians u.s. investigational device exemption (ide) clinical trial of cguard at linc 2024

Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial
NSPR Ratings Summary
NSPR Quant Ranking